Einträge von Conrad, Beate auf dem Publikationsserver

Livingstone, Elisabeth, Zimmer, Lisa, Hassel, Jessica C., Fluck, Michael, Eigentler, Thomas K., Loquai, Carmen, Haferkamp, Sebastian , Gutzmer, Ralf, Meier, Friedegund , Mohr, Peter, Hauschild, Axel, Schilling, Bastian, Menzer, Christian , Kiecker, Felix, Dippel, Edgar, Roesch, Alexander, Ziemer, Mirjana, Conrad, Beate, Körner, Silvia, Windemuth-Kieselbach, Christine, Schwarz, Leonora, Garbe, Claus, Becker, Jürgen C., Schadendorf, Dirk, Livingstone, Elisabeth, Zimmer, Lisa, Hassel, Jessica C., Fluck, Michael, Eigentler, Thomas K., Loquai, Carmen, Haferkamp, Sebastian, Gutzmer, Ralf, Meier, Friedegund, Mohr, Peter, Hauschild, Axel, Schilling, Bastian, Menzer, Christian, Kiecker, Felix, Dippel, Edgar, Roesch, Alexander, Ziemer, Mirjana, Conrad, Beate, Körner, Silvia, Simon, Jan-Christoph, Herbst, Rudolf A., Berking, Carola, Utikal, Jochen, Sell, Sabine, Martens, Uwe M., Terheyden, Patrick, Stadler, Rudolf, Windemuth-Kieselbach, Christine, Schwarz, Leonora, Garbe, Claus, Becker, Jürgen C. und Schadendorf, Dirk (2022) Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial. The Lancet 400 (10358), S. 1117-1129. Volltext nicht vorhanden.

Zimmer, Lisa, Livingstone, Elisabeth, Hassel, Jessica C., Fluck, Michael, Eigentler, Thomas, Loquai, Carmen, Haferkamp, Sebastian, Gutzmer, Ralf, Meier, Friedegund, Mohr, Peter, Hauschild, Axel, Schilling, Bastian, Menzer, Christian, Kieker, Felix, Dippel, Edgar, Rösch, Alexander, Simon, Jan-Christoph, Conrad, Beate, Körner, Silvia, Windemuth-Kieselbach, Christine, Schwarz, Leonora, Garbe, Claus, Becker, Jürgen C., Schadendorf, Dirk, Berking, Carola, Herbst, Rudolf A., Martens, Uwe M., Sell, Sabine, Stadler, Rudolf, Terheyden, Patrick und Utikal, Jochen (2020) Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet 395 (10236), S. 1558-1568. Volltext nicht vorhanden.